^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PF-07224826
i
Other names: PF-07224826, PF 07224826, PF07224826
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pfizer
Drug class:
CDK4 inhibitor, CDK6 inhibitor, CDK2 inhibitor
Related drugs:
1year
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=0, Withdrawn, Pfizer | N=110 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
fulvestrant • PF-07224826
over1year
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=110, Not yet recruiting, Pfizer | Trial completion date: Oct 2027 --> Apr 2028 | Initiation date: Jul 2023 --> Jan 2024 | Trial primary completion date: Oct 2025 --> Apr 2026
Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
fulvestrant • PF-07224826
over1year
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=110, Not yet recruiting, Pfizer
New P1 trial • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
fulvestrant • PF-07224826
Share via
